Table 2.

Summary of hemoglobin efficacy data (intent-to-treat population)

HemoglobinDaprodustat, n=133Darbepoetin Alfa, n=134
Baseline Hgb, g/dl
n133134
 Mean (SD)10.9 (0.8)10.8 (0.7)
Mean Hgb during wk 40–52, g/dl
n120125
 Mean (SD)10.9 (0.7)10.8 (0.6)
 Change from baseline (SD)0.0 (1.0)0.0 (0.8)
Adjusted mean Hgb during wk 40–52, g/dl
 Adjusted mean (95% CI)10.9 (10.8 to 11.0)10.8 (10.7 to 11.0)
 Adjusted treatment difference (95% CI) for mean Hgb during wk 40–520.1 (−0.1 to 0.2)
No. (%) of participants with mean Hgb within target during wk 40–52a
n120125
 No. of participants (%)105 (88)113 (90)
  • Change from baseline in mean Hgb during weeks 40–52 was performed in a post hoc analysis. Adjusted values were estimated by a mixed model for repeated measures as specified in Statistical Analyses. ITT, intent-to-treat; Hgb, hemoglobin; 95% CI, 95% confidence interval.

  • a Modified ITT population.